Cytosorbents (CTSO) Misses Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
CytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook
March 8, 2022 4:15 PM ESTMONMOUTH JUNCTION, N.J., March 8, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported audited financial and operating results for the quarter and year ended December 31, 2021 and provides its 2022 outlook.
... More
